April 2025 Newsletter

Published:  
04/16/2025
Categories:  
Blog - Melanoma360
Image

This month, we delve into one of the most groundbreaking developments in melanoma research: vaccines. Our spotlight article examines the potential of mRNA vaccines and explores the progress researchers have made toward creating a melanoma-specific vaccine.You’ll also find the latest installment of our Side Effect Central series—this issue covers lichen planus, an inflammatory skin condition that can appear during treatment with immunotherapy, with insights to help patients and caregivers understand and manage this potential side effect.

We also highlight a compelling study on indoor tanning behaviors, revealing how some individuals continue to tan indoors despite knowing the serious health risks—offering new understanding around the concept of behavioral addiction.

Whether you want to stay updated on the latest melanoma research, support a loved one facing the disease, or expand your understanding of it, this issue is filled with valuable insights and resources to guide you.

Read. Learn. Stay connected with AIM.

Recent Posts

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Jun. 09, 2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Filter by Tag